Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Abstract

Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.